The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.n

Tumor lysis syndrome (TLS)

Publications

Kulkarni HS, Kasi PM

Rituximab and cytokine release syndrome.

Case reports in oncology. 2012;5(1):134-41

Yang B, Lu XC, Yu RL, Chi XH, Zhang WY, Zhu HL, Yuan J, Zhao P

Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma.

The American journal of the medical sciences. 2012;343(4):337-41

Francescone SA, Murphy B, Fallon JT, Hammond K, Pinney S

Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder.

Transplantation proceedings. 2009;41(5):1946-8

Jabr FI

Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.

International journal of hematology. 2005;82(4):312-4